CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
复制标题
DOI：
10.1002/cyto.b.21745
复制
发表时间：
2019-03-01
影响因子：
3.4
通讯作者：
van der Velden, Vincent H. J.
中科院分区：
文献类型：
--
作者：
Bras, Anne E.;de Haas, Valerie;van der Velden, Vincent H. J.
背景虽然已知CD 123通常在浆细胞样树突状细胞上强烈表达，而在有核红细胞上完全不表达，但关于急性白血病中CD 123表达的详细信息很少，并且即使可用，由于方法学不同而难以比较。193例儿童BCP-ALL、69例成人BCP-ALL、101例儿童T-ALL和28例成人T-ALL患者。57例AML和19例BCP-ALL患者的配对诊断-复发样本可用。32例儿童AML患者的白血病干细胞（LSC）数据可用。根据平均荧光强度、中值荧光强度和CD 123阳性细胞百分比评估CD 123表达。CD 123在大多数AML和BCP-ALL患者中表达，而在大多数T-ALL患者中不表达。在AML中，CD 123表达在红系/巨核细胞白血病中较低，在NPM 1突变和FLT 3-ITD突变白血病中较高，并且在LSC和白血病原始细胞之间相当。在BCP-ALL中，（高）超二倍体核型和BCR-ABL融合基因患者的CD 123表达较高。有趣的是，CD 123表达增加BCP-ALL复发，而高度可变的AML复发（相比CD 123表达在诊断）。结论作者评估了CD 123表达在一个大型队列的急性白血病患者，基于标准化和可重复的方法。我们的研究结果可能有助于对最有可能对CD 123靶向治疗有反应的患者进行分层，并作为CD 123表达（健康和疾病）的参考。(c)2018作者细胞计数B部分：Wiley Periodicals，Inc.出版的临床细胞计数。国际临床细胞计数学会（International Clinical Cytometry Society）
Background While it is known that CD123 is normally strongly expressed on plasmacytoid dendritic cells and completely absent on nucleated red blood cells, detailed information regarding CD123 expression in acute leukemia is scarce and, if available, hard to compare due to different methodologies.Methods CD123 expression was evaluated using standardized EuroFlow immunophenotyping in 139 pediatric AML, 316 adult AML, 193 pediatric BCP-ALL, 69 adult BCP-ALL, 101 pediatric T-ALL, and 28 adult T-ALL patients. Paired diagnosis-relapse samples were available for 57 AML and 19 BCP-ALL patients. Leukemic stem cell (LSC) data was available for 32 pediatric AML patients. CD123 expression was evaluated based on mean fluorescence intensity, median fluorescence intensity, and percentage CD123 positive cells.Results EuroFlow panels were stable over time and between laboratories. CD123 was expressed in the majority of AML and BCP-ALL patients, but absent in most T-ALL patients. Within AML, CD123 expression was lower in erythroid/megakaryocytic leukemia, higher in NPM1 mutated and FLT3-ITD mutated leukemia, and comparable between LSC and leukemic blasts. Within BCP-ALL, CD123 expression was higher in patients with (high) hyperdiploid karyotypes and the BCR-ABL fusion gene. Interestingly, CD123 expression was increased in BCP-ALL relapses while highly variable in AML relapses (compared to CD123 expression at diagnosis).Conclusions Authors evaluated CD123 expression in a large cohort of acute leukemia patients, based on standardized and reproducible methodology. Our results may facilitate stratification of patients most likely to respond to CD123 targeted therapies and serve as reference for CD123 expression (in health and disease). (c) 2018 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals, Inc. on behalf of International Clinical Cytometry Society.